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Argireline® is well known, innovative anti-aging product 
used in the cosmetic market. This short chain peptide 
is used as active ingredient in dermal ointments and 
creams. Argireline® prevents formation of skin lines and 
wrinkles in a very similar way to the botulinum toxin 
(Botox), inhibiting neurotransmitter release at the neu-
romuscular junction. Argireline® does not require under 
skin muscle injections and it is believed to be relatively 
safe. However, despite the fact that some toxicity data 
has been provided by the product manufacturer, there 
is an evident lack of reliable information about cyto-
toxicity of argireline® in the literature. The aim of the 
presented study was to estimate the antiproliferation 
effect of argireline® solution in several concentrations. 
The influence of argireline® on cellular proliferation was 
examined against: human embryonic kidney HEK-293 
cell line, human neuroblastoma IMR-32 cell line, and 
human primary skin fibroblasts. Tests were performed 
using formazan-based cell proliferation assay: EZ4U, 
which allows to measure the efficiency of mitochondrial 
oxidative activity in living cells. The argireline® inhibi-
tory concentration, IC50 values were calculated and the 
results were compared to the IC50 value of the reference 
compound: doxorubicin. In conclusion, the considered 
method resulted in dose-dependent argireline® anti-
proliferation effects. However, the significant cytotoxicity 
of argireline® solution was observed under 18 to 10  000 
fold higher concentrations (depending on cells that were 
examined) in comparison to doxorubicin.
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INTRODUCTION
Over the last years cosmetic industry has been ex-
tensively developed towards biologically active products 
with drug-like effects. Cosmetic applied topically, such 
as creams, lotions and ointments can contain small bi-
ological active chemical compounds like: carbohydrates, 
lipids, antioxidants, peptides, and proteins (Schroeder, 
2012). They are used in anti-solar, anti-aging, anti-wrin-
kle and firming products. Those active compounds help 
to improve appearance of aging skin by bettering its hy-
dration, firmness and texture (Lupo et al., 2007). Peptides 
are being incorporated in cosmetic formulas thanks to 
their wide biological effects. They play important role 
in aging, inflammation, cell proliferation and migration, 
angiogenesis, protein synthesis and regulation, pigmenta-
tion, and in extracellular matrix synthesis (Zhang et al., 
2009). Cosmeceutical peptides are believed to be rela-
tively safe, but the information about their cytotoxicity 
is still insufficient. Therefore the aim of presented study 
was to estimate the anti-proliferation effect of argireline® 
0.05% solution, as an example of peptide used in cos-
metic market. 
Argireline® (acetyl hexapeptide-3, MW=889.1 g/mol) 
is a synthetic anti-aging peptide produced by Lipotec 
LTD. company (Neuronal exocytosis inhibiting peptides 
and cosmetic and pharmaceutical compositions contain-
ing said peptides, WO 00/64932, 2002, Lipotec LTD). 
In cosmetic products it is a biological active formulation 
ingredient, present most often in form of a powder or 
0.05% Argireline® solution. Argireline® belongs to neu-
rotransmitters inhibiting cosmeceutical peptide category. 
It has been derived from N-terminal end of SNAP-25 
protein (aa 12–17) with following amino acid sequence: 
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (Fig. 1).
Argireline® acts in similar way as botulinum neuro-
toxins (Botox®, Allergan, Irvine, CA) causing muscle 
paralysis by inhibiting activity in the presynaptic neu-
ronal exocytosis machinery (Fields et al., 2008). Active 
peptide inhibits skin muscle contraction, especially in 
the forehead, neck, nasal flare and around the eyes 
(Gorouhi et al., 2009). Argireline® is blocking Ca2+ 
dependent neurotransmitter release (acetylcholine) at 
neuromuscular junction. This peptide is reacting with 
SNARE complex, consisting of three synaptic proteins 
SNAP-25, VAMP and syntaxin. Argireline® competes 
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Figure 1. The chemical structure of argireline® (Blanes-Mira et 
al., 2002).
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with the SNAP-25 protein in the SNARE complex, 
essential for neuronal exocytosis, (Chen et al., 2001). 
Due this complex is destabilized, preventing catechol-
amine and acetylcholine vesicle fusion with plasma 
membrane (Fields et al., 2008). This peptide can sig-
nificantly limit neurosecreation at micromolar concen-
tration (Blanes-Mira at al., 2002). The effectiveness of 
argireline® has been confirmed in several anti-wrinkle 
tests performed in vitro using chromaffin cells and in 
vivo on healthy volunteers. A clinical study published 
in the International Journal of Cosmetic Science reported 
that acetyl hexapeptide-3 at a 10% concentration in 
O/W emulsion reduces the depth of wrinkles up to 
30% after 30 days of use (Blanes-Mira at al., 2002). 
Although the anti-wrinkle effect of argireline® is now 
commonly known and well described in the litera-
ture, the cytotoxicity data of this compound was only 
found in commercial data sheets*. According to those 
data no signs of cytotoxicity were observed on human 
dermal fibroblasts and human epidermal keratinocytes, 
when argireline was administrated in concentrations 
between 10 μg/ml and 1 mg/ml. Also no genotox-
icity was observed testing argireline® in concentra-
tions ranging from 5 to 0.05 mg/plate in Ames test, 
performed on several S. typhymurium strains: TA97, 
TA98, TA100, TA 102 and TA 1537. The acute oral 
toxicity of argireline® has been also investigated. Ac-
cording to authors this small peptide exhibits its in-
significant acute toxicity (2000 mg/kg) as compared 
with BTX-A (20 ng/kg) (Blanes-Mira at al., 2002). 
Considering presented data we demonstrated indepen-
dent study of antiproliferation effect of argireline® on 
human embryonic kidney HEK-293 cell line, human 
neuroblastoma IMR-32 cell line, and human primary 
skin fibroblasts. Experiments have been performed 
using formazan-based antiproliferation assay: EZ4U, 
which allows to measure the efficiency of mitochon-
drial oxidative activity in living cells. This test takes 
advantage of enzymatic bioreduction of tetrazolium 
salt into formazan product which can be quantified 
using spectrofotometric methods (Malich et al., 1997; 
Krzysztoń-Russjan et al., 2009).
MATERIALS AND METHODS:
Reagents. Argireline® (MW=889,1g/mol) was kindly 
provided by Przedsiębiorstwo Produkcyjno-Handlowe 
Ryszard Kaczmarek i Synowie Sp. z o. o., Spółka Ko-
mandytowa, the official distributor of Lipotec S.A. prod-
ucts in Poland. Argireline was in form of 0.05% water 
solution. Concentration of pure active peptide in solu-
tion has been estimated around 0.56 mM, according to 
the information provided by manufacturer. Doxorubicin 
hydrochloride (2 mg/ml) was from Ebewe Pharma Po-
land. EZ4U Non-radioactive cell proliferation and cy-
totoxicity assay, was from Biomedica. For cell culture 
Dulbecco’s Modified Eagle’s Medium — DMEM (Gibco) 
was used, supplemented with fetal bovine serum (Gibco) 
and streptomycin/penicillin (Polfa Tarchomin).
Cell lines. Neuroblastoma IMR-32 cell line was pro-
vided by Department of Oncogenomics, Academisch 
Medisch Centrum, Amsterdam, Holland (Cheng et al., 
1995) (Tumilowicz et al., 1970). 
Human embryonic kidney HEK-293 cell line (ATCC 
CRL 1573) was kindly donated by Prof. Dr. Christa 
Müller (Pharmaceutical Institute, Pharmaceutical Chem-
istry I, University of Bonn). 
Human skin fibroblasts (HSF) were kindly provided 
by Prof. Justyna Drukała (Faculty of Biochemistry, Bio-
physics and Biotechnology of the Jagiellonian Universi-
ty). Human fibroblasts were isolated from skin graft, ob-
tained from 38 years old male patient. 
Cell culture. HEK-293 and IMR-32 cell lines, as well 
as human dermal fibroblasts were cultured in Dulbecco’s 
Modified Eagle’s complete growth Medium (DMEM); 
media contained 10% fetal bovine serum (FBS), 100 
mg/mL streptomycin and 100 U/mL penicillin. Cells 
were cultured at 37°C in an atmosphere containing 5% 
CO2.
In vitro proliferation assay using EZ4U. Cells were 
seeded in 96-well plates at a concentration of 2 × 104 
cells/well (IMR-32), 1.5 × 104 cells/well (HEK-293) and 
1 × 104 cells/well (HSF) in 200 μl culture medium and 
incubated for 24 h at 37°C and 5% CO2 to reach 60% 
confluence. Next, argireline® was added into microplates 
at the final concentrations 0.01 μM–100 μM. The cells 
were incubated with argireline® for 48 h at 37°C and 
5% CO2. Then, 20 μl of EZ4U labeling mixture was 
added and the cells were incubated for 5 h under the 
same conditions. The absorbance of the samples was 
measured using a microplate reader (PerkinElmer) at 
492 nm. The activity of the standard drug doxorubicin 
(DX) was estimated in the same way by using EZ4U at 
the concentrations 0.001–50 μM (against IMR-32) and at 
0.005–100 μM (against HEK-293) and at 0.005–50 μM 
(against HSF). All experiments were conducted in four 
repetitions. GraphPad Prism 5.01 software was used to 
calculate the experimental IC50 values.
*(www.lotioncrafter.com/pdf/argireline.pdf, 15.10.2013)
Figure 2. The antiproliferative effect of argireline® solution against HEK-293 (left) and IMR-32 (right) cell lines. 
Values represent the mean of n= 4 experiments.
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RESULTS AND DISCUSSION
Cytotoxicity tests, including formazan-based in vitro 
proliferation assays, are widely used in drug discovery 
research for testing safety of therapeutic agents before 
they are progressed to the clinic. The acceptable toxicity 
as well as the other parameters such as: absorption, dis-
tribution, metabolism, elimination, describe the ability of 
the compound to be an ideal drug candidate (Kerns et al., 
2008). Additionally, in-vitro toxicity testing is a reliable al-
ternative to the animals toxicity testing by reduction, re-
placement and refinement (3Rs) approach (Smith 2001). 
Argireline® is the peptide with very high biological ac-
tivity and therefore should be considered not only as an 
anti-wrinkle ingredient used in cosmetology but also as a 
potential toxic agent in case of long-term skin exposure 
or overdose. That justify the necessity of its safety test-
ing just as any other drug. The incubation of argireline® 
solution in different concentrations with human embry-
onic kidney HEK-293 and neuroblastoma IMR-32 cell 
lines for 48 h had dose dependent antiproliferative effect 
(Fig. 2). In lower concentration no difference between 
argireline® and the control without active peptide was 
observed on proliferative activity of the examined cells. 
However, the significant antiproliferative activity was ob-
served above 10 µM argireline® concentration. The cal-
culated IC50 values were 34.862 μM against HEK-293 
and 68.458 μM against IMR-32 respectively. 
The antiproliferative effect of the commonly used 
drug in cancer chemotherapy doxorubicin (DX) on 
HEK-293 and IMR-32 was also examined. This com-
pound is used in anticancer treatment and possesses well 
examined antiproliferative effects. Therefore, it is com-
monly used as a standard compound in comparison of 
cytotoxic properties of unknown substances. The ob-
tained data showed very strong antiproliferative effect 
of DX against neuroblastoma cell line IMR-32 (IC50 =  
0.0051 μM) and human embryonic kidney HEK-293 cell 
line (IC50 = 0.455 μM) (Fig. 3). Comparing the results 
of antiproliferative effect of argireline® and doxorubicin 
(standard compound), it has to be pointed out that the 
IC50 value of argireline® is almost 75 fold higher than 
IC50 of DX against HEK-293 cell line and more than 
10 000 fold higher against IMR-32 cell line.
Argireline® is a synthetic anti-aging peptide, applied 
topically, therefore we also examined its anti-proliferative 
effect on human skin cells. Argireline® solution incubat-
ed in different concentrations with HSF had a dose-de-
pendent antiproliferative effect on those cells (Fig. 4). 
Cellular proliferation was not effected in argireline® 
low concentration. The evident antiproliferative effect 
(67% inhibition) has been observed at 100 µM. The an-
tiproliferative effect of DX against HSF was also exam-
ined. The results are shown in Fig. 5.
Contrary to HEK-293 and IMR-32, doxorubicin was 
less cytotoxic against HSF, effecting these cells above 
1 µM (IC50 = 5.628 µM). In the comparison with other 
examined cells, the antiproliferative effect of DX against 
HSF was more than 700 fold lower for IMR-32 (IC50 
=  0.0051 μM) and 8 fold lower for HEK-293 (IC50 = 
0.455 μM). Comparing the results of the antiproliferative 
effect of argireline® and doxorubicin against HSF, the 
significant effect of argireline® was observed at 100 µM, 
whereas for doxorubicin at 18 fold lower concentration 
Figure 3. The antiproliferative effect of (DX) against HEK-293 (left) and IMR-32 (right) cell lines. 
Values represent the mean of n=4 experiments.
Figure 4. The antiproliferative effect of argireline® solution 
against human skin fibroblasts (HSF). 
Values represent the mean of n=4 experiments.
Figure 5. The antiproliferative effect of doxorubicin (DX) against 
human skin fibroblasts (HSF). 
Values represent the mean of n=4 experiments.
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5.628 µM. However, argireline® producer states that no 
signs of peptide cytotoxicity were observed on human 
dermal fibroblasts at concentrations between 10 μg/ml 
and 1 mg/ml*. This was not confirmed in our exper-
iments, where argireline exhibited 67% antiproliferative 
effect after 48 h of incubation at 100 µM (90 μg/ml ). 
Unfortunately, the detailed comparison study is impos-
sible due to unpublished data about the experiments 
which were undertaken by manufacturer. Therefore, fur-
ther antiproliferation study should be also performed to 
verify the manufacturer results for human epidermal ke-
ratinocytes. In conclusion, this comparative study reveals 
that argireline® seems to be a safe compound in com-
pare to the reference compound doxorubicin. Notwith-
standing this fact, taking to the account the cytotoxic ac-
tivity against human skin fibroblasts the safety profile of 
this product is of concern and the use of argireline® in 
very high doses or for a very long period of time must 
be considered as potentially dangerous for patients. 
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